Natriumcitrat Grifols (Sodium Citrate)

Sodium citrate acts by binding free calcium ions in the bloodstream. Calcium is essential for several steps in the coagulation cascade; when citrate chelates calcium, those calcium‑dependent reactions are inhibited, thereby reducing the ability of blood to clot while it circulates through extracorporeal devices.

The dose of sodium citrate is individualized by the treating physician based on the specific procedure, patient weight, renal function, and laboratory monitoring. Clinicians calculate the infusion rate to achieve the desired anticoagulation level while regularly checking calcium and coagulation parameters.

Data on sodium citrate use in pregnancy and lactation are limited. It should only be used when clearly needed and when the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers should discuss the risk‑benefit profile with the patient before initiating therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with heparin, sodium citrate provides regional anticoagulation without systemic anticoagulant effects, as its action is largely confined to the circuit where calcium is chelated. This can reduce bleeding risk after the procedure, but requires careful monitoring of calcium levels and may need calcium replacement post‑treatment.

Natriumcitrat Grifols should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations. Ensure the container is tightly sealed to maintain sterility and potency until use.

The product is administered intravenously into the extracorporeal circuit, typically via a dedicated infusion line. The infusion rate is adjusted by the clinical team according to the procedure’s anticoagulation requirements and is continuously monitored with calcium and coagulation assays.

The most serious risks include severe hypocalcemia, which can cause tetany, seizures, or cardiac arrhythmias, and profound hypotension that may require immediate intervention. Metabolic alkalosis and rare anaphylactic reactions are also possible, so patients must be closely monitored throughout the infusion.

Patients with known hypersensitivity to citrate, uncontrolled severe hypocalcemia, or those who cannot be monitored for calcium levels should avoid sodium citrate. Additionally, individuals with severe cardiac instability or who are receiving incompatible calcium‑binding agents may be contraindicated for this therapy.